Address
1281 W.Green Oaks Suite 129 Arlington, TX 76013
Our weight loss program is designed to support sustainable results through individualized assessment, prescription therapy when appropriate, nutrition counseling, movement planning, and metabolic support.
Each plan is tailored to your goals, health history, body composition, and metabolic needs. Weight loss is not treated as a one-size-fits-all process — it is approached as a whole-person journey.
mean body-weight reduction reported with semaglutide in the STEP 1 trial
mean weight reduction reported with tirzepatide in SURMOUNT-1
phase 2 retatrutide study result; still investigational and not FDA-approved
U.S. adult obesity prevalence reported by CDC/NCHS for Aug 2021–Aug 2023
Our program combines medical supervision with lifestyle coaching and supportive wellness strategies so progress is both measurable and sustainable.
Body composition analysis
Medical evaluation
GLP-1 / GIP options when appropriate
Nutrition counseling
Exercise planning
Metabolic wellness support
We use structured medical monitoring, clear dose-escalation plans, behavior coaching, and supportive therapies for energy, hydration, and recovery.
We look beyond the scale to track fat mass, lean mass, and overall progress so the plan can be adjusted with greater precision.
When clinically appropriate, semaglutide or tirzepatide may be included as part of a full program with ongoing provider monitoring.
Medication works best alongside reduced-calorie nutrition, adequate protein, hydration, movement, resistance training, and sustainable habit change.
Wellness injections, infusion therapy, and supportive services may be used to help with hydration, nutrient replenishment, and metabolic support.
Follow-up visits help track progress, address side effects, and keep your treatment aligned with your long-term goals.
Every plan is built around your history, response to treatment, and lifestyle so the process feels practical, medical, and personal.
FDA-approved obesity medications such as semaglutide and tirzepatide are intended to be used in addition to reduced-calorie nutrition and increased physical activity, not instead of them.
Semaglutide also carries FDA approval to reduce the risk of major adverse cardiovascular events in certain adults with obesity or overweight and established cardiovascular disease.
Retatrutide is currently investigational and not FDA-approved for weight loss.
If compounded medication is used, patients should understand that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality before marketing.
Products should only come from carefully vetted pharmacies operating under applicable federal and state requirements. Patients should never purchase products labeled for “research use only” or “not for human consumption.”
Selected references:
CDC/NCHS obesity prevalence data, STEP 1 semaglutide trial, SURMOUNT-1 tirzepatide trial, FDA Wegovy and Zepbound guidance, Wegovy cardiovascular risk-reduction update, and phase 2 retatrutide research.
If you are looking for evidence-based, medically supervised weight loss support, we can help create a plan that matches your health history and long-term goals.
We help patients build safer, more sustainable progress through individualized assessment, treatment planning, and ongoing clinical support.
Feel Stronger. Live Better.